Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 2.4% in the afternoon session after the stock extended its negative momentum as Piper Sandler initiated coverage of the stock with a Neutral ...
Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 2.1% in the morning session after Piper Sandler initiated coverage on the stock with a Neutral rating and a $15.00 price target. While the ...
Hosted on MSN
Guggenheim Downgrades 10x Genomics (TXG)
Fintel reports that on June 26, 2024, Guggenheim downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from Buy to Neutral. Analyst Price Forecast Suggests 109.23% Upside As of June 12, 2024, the ...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...
Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded ...
I assign TXG a buy rating with a 1-year price target of $12.7 per share, projecting an 18% upside YoY. TXG's new lower-cost Chromium offerings could drive volume growth and increased adoption, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback